trial

Imaging Synapses With [11C] UCB-J in the Human Brain

NCTId NCT04038840
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 60 (estimated)
Sponsored by Davidzon, Guido, M.D.
Primary completion 2025-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2019-08-01
Primary completion
2025-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
[11C]UCB-J radiotracerPET-MR

Sponsors

Davidzon, Guido, M.D.Lead Sponsor
Weston Havens FoundationCollaborator

Investigators

1
Jong H. Yoon, MDPrincipal Investigator

Sites

2 total
Palo Alto, United StatesStanford, United States

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE1
Primary Completion Date
2025-12
Status
RECRUITING
relationships
The graph out of here
drug
[11C]UCB-J radiotracer
drug
PET-MR
drug
lead_sponsor
Davidzon, Guido, M.D.
company
collaborator
Weston Havens Foundation
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jong H. Yoon, MD
person